21(st) Century Cures Act: An Act of Cure or Diagnosis?

The 21st Century Cures Act1 is a positive step for biomedical innovation. However, despite a rare bipartisan approval in the House of Representatives with an overwhelming vote of 344–77, public opinion is divided; naysayers have already vocally claimed that the reforms do not go far enough, while others have criticized the bill for promoting increased approval speeds at the expense of patient safety.2 As biomedical researchers and patients wanting novel, and safe, therapies to reach the market, it is difficult not to sympathize with negative factions; but is this fair or productive?